NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

368.45 -7.65 (-2.03%)

High vol. this week

NSE 18 Sep, 2026 3:31 PM (IST)

16,082.8

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Search Inside the pdf :

Emami Ltd.

06 Aug 2026

368.45

-2.03%

Domestic growth and strategic acquisitions offset international headwinds

Buy: Emami Ltd.

Target

Khambatta Securities

Emami Limited reported a healthy 1Q FY27, with consolidated revenue growing 15% y-o-y to Rs. 1,039.2 crore, led by 20% growth in domestic business.

Emami Ltd. has an average target of 577.25 from 5 brokers.

Emami Ltd.

26 May 2026

368.45

-2.03%

Geopolitical and seasonal headwinds drag 4Q FY26; recovery expected in 1H FY27

Buy: Emami Ltd.

Target

Khambatta Securities

Emami Limited reported a weak 4Q FY26 performance, dragged primarily by two external headwinds -- unseasonably delayed summer season that dented the summer portfolio and geopolitical disruptions in Middle East that impacted the international business. Despite these temporary setbacks, the underlying strength of the core domestic portfolio remained intact.

Emami Ltd. is trading below all available SMAs

Emami Ltd.

06 Apr 2026

368.45

-2.03%

News in the Nutshell

Not Rated: Emami Ltd.

Deven Choksey

Emami Ltd. Has broadened its presence in the Ayurveda Beverage segment by increasing the stake to 100% in the Axiom Ayurveda making it as its wholly owned subsidiary. Emami previously held 26.5% stake in Axiom which it acquired in October 2023.

Promoters unpledged 0.20% of shares in last quarter. Total pledge stands at 16.23% of promoter holdings

Emami Ltd.

09 Feb 2026

368.45

-2.03%

Seasonal tailwinds and GST normalization drive volume-led recovery

Buy: Emami Ltd.

Target

Khambatta Securities

Emami's performance in 3Q FY26 showed broad-based recovery. Management is optimistic about 4Q FY26 and beyond. They are targeting double-digit growth for their brand teams, particularly as GST rates have now stabilized at 5% for ~88% of the portfolio and trade channels.

Emami has lost -36.43% in the last 1 Year

Emami Ltd.

04 Feb 2026

368.45

-2.03%

Steady show; positive commentary on growth recovery

Buy: Emami Ltd.

Target

Motilal Oswal

Emami’s consolidated revenue grew 10% YoY in 3QFY26 (in line), backed by a favorable winter season. Emami saw a sequential improvement following the GST 2.0-related trade disruptions in the early part of 3Q.

Promoters unpledged 0.20% of shares in last quarter. Total pledge stands at 16.23% of promoter holdings

Emami Ltd.

04 Feb 2026

368.45

-2.03%

Emami (HMN IN) Q3FY26 Result Update Demand outlook cautiously optimistic Accumulate

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

HMN reported a growth of ~9.8%/9% in sales/volumes on strong winters, and normalization of channel inventory post GST led to disruption. Near-term outlook remains optimistic given 1) Healthy demand outlook for Q4 led by prolonged winters 2) Revival in rural demand with focus on small SKUs in shampoos and skin creams and 3) initial gains form revamp and relaunch of Kesh King, with a new proposition, packaging and formulation. Although...

Emami Ltd. has an average target of 577.25 from 5 brokers.

Emami Ltd.

29 Nov 2025

368.45

-2.03%

Emami Limited Tgt 613

Buy: Emami Ltd.

BP Wealth

Emami operates primarily in beauty and healthcare, offering more than 550 products across categories such as skin care, hair care, pain management balms, cooling oils, and over-the-counter healthcare remedies. Its portfolio includes power brands like Navratna cooling oil, BoroPlus antiseptic cream, Zandu Balm, Mentho Plus, Kesh King hair oil, and Smart & Handsome (earlier Fair & Handsome) men's grooming range, many of which enjoy leadership positions in their respective niches. The company generated around Rs. 3,800+ crores in turnover in FY25, positioning it among India's larger listed FMCG companies by revenue. Emami's products are available through a wide distribution network spanning over 5.4 million retail outlets in India serviced by more than 3,400 distributors, and a global footprint in 70+ countries across SAARC, Middle East, Africa, CIS, and parts of Europe and Southeast Asia. A key pillar of Emami's strategy is continuous brand-building and innovation in ayurvedic and natural propositions that resonate strongly with Indian consumers. The...

Promoters unpledged 0.20% of shares in last quarter. Total pledge stands at 16.23% of promoter holdings

Emami Ltd.

27 Nov 2025

368.45

-2.03%

GST changes slows quarter; new product launches drive confidence for FY27

Buy: Emami Ltd.

Target

Khambatta Securities

Emami's performance in 2Q FY26 was impacted by external, non-recurring factors primarily related to the GST rate changes. Management is optimistic about a rebound in the second half of FY26.

Emami Ltd. is trading below all available SMAs

Emami Ltd.

10 Nov 2025

368.45

-2.03%

Emami (HMN IN) Q2FY26 Result Update GST impact...

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

Emami Ltd. has an average target of 577.25 from 5 brokers.

Emami Ltd.

10 Nov 2025

368.45

-2.03%

Weak delivery; recovery seems slower than anticipated

Buy: Emami Ltd.

Target

Motilal Oswal

Emami’s consolidated revenue declined 10% in 2QFY26 (inline), impacted by GST 2.0-led temporary trade disruptions in Sep’25 and extended monsoon affecting the summer portfolio.

Number of FII/FPI investors decreased from 270 to 252 in Jun 2026 qtr

Is Emami Ltd. worth buying?

241 Votes:

Buy 74.27%

Sell 17.43%

Hold 8.3%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf